Available Forms: Injection
Available Strengths: 350 mg/20 mL
Reference Brands: Kisunla(USA)
Category: Neurology
Donanemab-azbt is a humanized immunoglobulin G1 monoclonal antibody directed against insoluble, N‑truncated pyroglutamate amyloid‑beta found in amyloid plaques in the brains of patients with Alzheimer’s disease. Its mechanism involves binding to these amyloid plaques and facilitating their removal (via microglial-mediated phagocytosis), thereby reducing amyloid burden in the brain. Use of donanemab has been shown to slow cognitive and functional decline in adults with early symptomatic Alzheimer’s disease (mild cognitive impairment or mild dementia) who have confirmed amyloid pathology.
Quick Response Guaranteed | Verified Suppliers
Donanemab-azbt is an experimental drug under investigation for the treatment of Alzheimer’s disease. It is designed to target and remove amyloid-beta plaques in the brain, which are associated with the progression of Alzheimer’s.
It is made from a humanized monoclonal antibody that specifically binds to modified amyloid-beta proteins in the brain.
There is currently no approved trade name, as the drug is still in clinical trials.
Donanemab is developed by Eli Lilly and Company.
The generic name is donanemab-azbt.
No brand name has been assigned yet.
It is manufactured in specialized biopharmaceutical facilities, primarily in the USA, under controlled conditions for clinical development.
Strength: 125 mg/mL, 200 mg, 250 mg, 300 mg, 500 mg, 100 mg/mL
Form: Tablet / Capsule/ Injection / Oral syrup
Reference Brands: Depakene (USA), Depakine (EU/LATAM), Valprol (India)
Strength: 50 mg, 100 mg
Form: Tablets
Reference Brands: Ubrelvy (USA/India)
Strength: 100 mg
Reference Brands: Tasmar (USA/EU)
Strength: 50 mg ,100 mg
Reference Brands: Xadago (USA/EU)
By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under ‘Fair use.’
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Stay updated on pharma trends and marketplace opportunities.
Online · B2B Pharma · Medical Tourism · NPP